Company intelligence / Profile preview

ScaleReady

St. Paul, Minnesota, United Statesscaleready.com ↗

Ownership: Private
Employees: ~32
Development stage: Commercial

Overview

ScaleReady’s G-Rex platform supports the manufacture of cell and gene-modified therapies. The technology underpins approximately 50% of CGT clinical trials globally and five commercially approved CGT drugs. Its solutions enable rapid expansion of T cells/NK cells with high reproducibility from research to GMP scale.

Therapeutic areas: Oncology
Modalities: Cell therapyGene therapyCAR-T cell therapyNK cell therapy
Industry: Non-Drug Biotech

Partnerships

Bio-Techne (reagents/cytokines)Wilson Wolf Manufacturing (bioreactors)Fresenius Kabi (cell processing automation)CellReadyAcademic/industry collaborations via the G-Rex Grant Program with institutions like USC, CHLA, A2 Biotherapeutics Inc., March Biosciences, Immuneel Therapeutics Limited

Beyond the preview

Go deeper on ScaleReady.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ScaleReady.

Explore the full profile